The effects of 8-year pamidronate treatment on skeletal morbidity in patients with advanced multiple myeloma

Nowotwory

Volumn 54, Issue 6, 2004, Pages 570-577

  Kraj, Maria ^a   Pogłód, Ryszard ^a   Maj, Stanisław ^a   Pawlikowski, Jan ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Bisphosphonates; Multiple myeloma; Osteolytic lesions; Pamidronate

Indexed keywords

ALBUMIN; ANALGESIC AGENT; CALCIUM; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE PAIN; BONE RADIOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERCALCEMIA; LONG TERM CARE; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PATHOLOGIC FRACTURE; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION; SURVIVAL; VERTEBRA FRACTURE;

EID: 12544259076     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Yaccoby S, Pearse RN, Johnson CL et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116: 278-90.
2. Kraj M. New concepts in the pathogenesis of myeloma bone disease. Acta Haemat Pol 2003; 34 suppl.1: 105-12.
3. Nakagawa M, Kaneda T, Arakawa T et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161-4.
4. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-94.
5. Iguchi T, Miyakawa Y, Yamamoto K et al. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 2003; 15: 719-27.
6. Kunzmann V, Bauer E, Feurle J et al. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384-92.
7. Gordon S, Helfrich MH, Sati HIA et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002; 119: 475-83.
8. Viereck V, Emons G, Lauck V et al. Bisphosphonates, pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002; 291: 680-6.
9. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-93.
10. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593-602.
11. Terpos E, Palermos J, Tsionos K et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000; 65: 331-6.
12. 2-microglobulin in multiple myeloma. Eur J Haematol 2003; 70: 34-42.
13. Kraj M, Pogłód R, Pawlikowski J et al. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Acta Pol Pharm 2000; 57 suppl: 113-6.
14. Kraj M, Pogłód R, Pawlikowski J, Maj S. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. Acta Haemat Pol 2000; 31: 379-89.
15. Kraj M, Pogłód R, Pawlikowski J, Maj S. The effect of very-long term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. 1. Int J Hematol 2000; 72 suppl 1: 99. 2. Hematol J 2001; 1 suppl.1: 33.3.Acta Haemat Pol 2003; 34 supl. 1: 400.
16. Kraj M, Pogłód R, Pawlikowski J, Maj S. The effect of very-long term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. 1. Int J Hematol 2000; 72 suppl 1: 99. 2. Hematol J 2001; 1 suppl.1: 33.3.Acta Haemat Pol 2003; 34 supl. 1: 400.
17. Kraj M, Pogłód R, Pawlikowski J, Maj S. The effect of very-long term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. 1. Int J Hematol 2000; 72 suppl 1: 99. 2. Hematol J 2001; 1 suppl.1: 33.3.Acta Haemat Pol 2003; 34 supl. 1: 400.
18. Kraj M, Pogłód R, Sokolowska U, Maj S. Long-term clodronate treatment reduces skeletal morbidity but does not prolong survival of multiple myeloma patients. Acta Haemat Pol 1999; 30: 399-407.
19. Rosen LS, Gordon D, Kamiński M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-87.
20. Rosen LS, Gordon D, Kamiński M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. A randomized, double blind, multicenter, comparative trial. Cancer 2003; 98: 1735-44.
21. Kraj M, Pogłód R, Maj S et al. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients. Acta Pol Pharm 2002; 59: 478-82.
22. Kraj M, Pogłód R, Maj S et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate in the treatment of myeloma bone disease. Acta Haemat Pol 2004; 35: 227-41.
23. Menssen HD, Sakalova A, Fontana A et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002; 20: 2353-59.
24. Brincker H, Westin J, Abildgaard N et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish Co-operative Study Group. Br J Haematol 1998; 101: 280-6.
25. McCloskey EV, MacLennan IC, Drayson MT et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998; 100: 317-25.
26. McCloskey EV, Dunn JA, Kanis JA et al. Long - term follow-up of a prospective, double blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001; 113: 1035-43.
27. Man Z, Otero AB, Rendo P et al. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990; 335: 663.
28. Thiebaud D, Leyvraz S, von Fliedner V et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991; 27: 37-41.
29. Nussbaum SR, Younger J, Vandepol CJ et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcaemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297-304.
30. Kraj M, Pogłód R, Mendek-Czajkowska E, Owczarska K. Reparacja szpiczakowych uszkodzeń osteolitycznych krȩgów w wyniku leczenia napromienianiem i pamidronianem lub kwasem zoledronowym. Acta Haemat Pol 2003; 34 supl.2: 397.
31. Djulbegovic B, Wheatley K, Ross J et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002; 3: CD003188.
32. Goldschmidt HG, Djulbegovic B, Cremer FW et al. Meta-analysis of published randomized trials on bisphosphonates in multiple myeloma. Hematol J 2001; suppl.1: 33.
33. Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719-36.